Colin Dunstan

List of Publications by Year
in descending order

183 papers	37,049 citations	11639 70 h-index	3822 178 g-index
196 all docs	196 docs citations	196 times ranked	20652 citing authors

#	Article	IF	Citations
1	Design and evaluation of 3D-printed Sr-HT-Gahnite bioceramic for FDA regulatory submission: A Good Laboratory Practice sheep study. Acta Biomaterialia, 2023, 156, 214-221.	4.1	2
2	The aryl-ureido fatty acid CTU activates endoplasmic reticulum stress and PERK/NOXA-mediated apoptosis in tumor cells by a dual mitochondrial-targeting mechanism. Cancer Letters, 2022, 526, 131-141.	3.2	5
3	Functional Ultra-High Molecular Weight Polyethylene Composites for Ligament Reconstructions and Their Targeted Applications in the Restoration of the Anterior Cruciate Ligament. Polymers, 2022, 14, 2189.	2.0	4
4	Personalized Baghdadite scaffolds: stereolithography, mechanics and in vivo testing. Acta Biomaterialia, 2021, 132, 217-226.	4.1	21
5	PTU, a novel ureido-fatty acid, inhibits MDA-MB-231 cell invasion and dissemination by modulating Wnt5a secretion and cytoskeletal signaling. Biochemical Pharmacology, 2021, 192, 114726.	2.0	0
6	Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor-binding protein 7. Stem Cells Translational Medicine, 2020, 9, 403-415.	1.6	17
7	Baghdadite Ceramics Prevent Senescence in Human Osteoblasts and Promote Bone Regeneration in Aged Rats. ACS Biomaterials Science and Engineering, 2020, 6, 6874-6885.	2.6	10
8	High-Strength Fiber-Reinforced Composite Hydrogel Scaffolds as Biosynthetic Tendon Graft Material. ACS Biomaterials Science and Engineering, 2020, 6, 1887-1898.	2.6	25
9	A comparative histomorphological and micro computed tomography study of the primary stability and the osseointegration of The Sydney Mini Screw; a qualitative pilot animal study in New Zealand rabbits. European Journal of Orthodontics, 2019, 41, 360-369.	1.1	3
10	A Novel Bone Substitute with High Bioactivity, Strength, and Porosity for Repairing Large and Loadâ€Bearing Bone Defects. Advanced Healthcare Materials, 2019, 8, e1801298.	3.9	43
11	Architectural Design of 3D Printed Scaffolds Controls the Volume and Functionality of Newly Formed Bone. Advanced Healthcare Materials, 2019, 8, e1801353.	3.9	89
12	Nanoemulsion-Enabled Oral Delivery of Novel Anticancer Ï‰-3 Fatty Acid Derivatives. Nanomaterials, 2018, 8, 825.	1.9	20
13	Effects of Materialâ€“Tissue Interactions on Bone Regeneration Outcomes Using Baghdadite Implants in a Large Animal Model. Advanced Healthcare Materials, 2018, 7, e1800218.	3.9	24
14	Priming Adipose Stem Cells with Tumor Necrosis Factor-Alpha Preconditioning Potentiates Their Exosome Efficacy for Bone Regeneration. Tissue Engineering - Part A, 2017, 23, 1212-1220.	1.6	146
15	A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells. Journal of Medicinal Chemistry, 2017, 60, 8661-8666.	2.9	17
16	Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/Î²-catenin signaling. Bone Research, 2017, 5, 17023.	5.4	43
17	The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget, 2017, 8, 26687-26701.	0.8	22
18	Efficacy of novel synthetic bone substitutes in the reconstruction of large segmental bone defects in sheep tibiae. Biomedical Materials (Bristol), 2016, 11, 015016.	1.7	30

#	Article	IF	Citations
19	Review: Photochemical Tissue Bonding (PTB) methods for sutureless tissue adhesion. International Journal of Adhesion and Adhesives, 2016, 71, 87-98.	1.4	18
20	Fracture behaviors of ceramic tissue scaffolds for load bearing applications. Scientific Reports, 2016, 6, 28816.	1.6	41
21	Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2. International Journal of Biochemistry and Cell Biology, 2016, 80, 173-178.	1.2	10
22	Characterisation of a novel light activated adhesive scaffold: Potential for device attachment. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 62, 433-445.	1.5	8
23	Zirconium Ions Up-Regulate the BMP/SMAD Signaling Pathway and Promote the Proliferation and Differentiation of Human Osteoblasts. PLoS ONE, 2015, 10, e0113426.	1.1	46
24	Histomorphological and torque removal comparison of 6 mm orthodontic miniscrews with and without surface treatment in New Zealand rabbits. European Journal of Orthodontics, 2015, 37, 578-583.	1.1	7
25	Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clinical and Experimental Metastasis, 2014, 31, 921-933.	1.7	36
26	Direct Crosstalk Between Cancer and Osteoblast Lineage Cells Fuels Metastatic Growth in Bone via Auto-Amplification of IL-6 and RANKL Signaling Pathways. Journal of Bone and Mineral Research, 2014, 29, 1938-1949.	3.1	33
27	Baghdadite Ceramics Modulate the Cross Talk Between Human Adipose Stem Cells and Osteoblasts for Bone Regeneration. Tissue Engineering - Part A, 2014, 20, 992-1002.	1.6	29
28	Fabrication of a novel triphasic and bioactive ceramic and evaluation of its in vitro and in vivo cytocompatibility and osteogenesis. Journal of Materials Chemistry B, 2014, 2, 1866.	2.9	15
29	Mathematical modeling of postmenopausal osteoporosis and its treatment by the antiâ€catabolic drug denosumab. International Journal for Numerical Methods in Biomedical Engineering, 2014, 30, 1-27.	1.0	44
30	Vitamin D supplements and bone mineral density. Lancet, The, 2014, 383, 1292.	6.3	1
31	Hypothesis: Bones Toughness Arises from the Suppression of Elastic Waves. Scientific Reports, 2014, 4, 7538.	1.6	20
32	Activation and promotion of adipose stem cells by tumour necrosis factorâ€alpha preconditioning for bone regeneration. Journal of Cellular Physiology, 2013, 228, 1737-1744.	2.0	68
33	Unique microstructural design of ceramic scaffolds for bone regeneration under load. Acta Biomaterialia, 2013, 9, 7014-7024.	4.1	51
34	The influence of bone surface availability in bone remodellingâ€"A mathematical model including coupled geometrical and biomechanical regulations of bone cells. Engineering Structures, 2013, 47, 134-147.	2.6	63
35	The role of the bone microenvironment in skeletal metastasis. Journal of Bone Oncology, 2013, 2, 47-57.	1.0	66
36	Computer Simulation-Based Modeling of the Pharmaceutical Intervention of Postmenopausal Osteoporosis by Denosumab. , 2012, , .		2

#	Article	IF	Citations
37	Repairing a critical-sized bone defect with highly porous modified and unmodified baghdadite scaffolds. Acta Biomaterialia, 2012, 8, 4162-4172.	4.1	101
38	Role of mathematical modeling in bone fracture healing. BoneKEy Reports, 2012, 1, 221.	2.7	49
39	Short-Term Exposure to Tumor Necrosis Factor-Alpha Enables Human Osteoblasts to Direct Adipose Tissue-Derived Mesenchymal Stem Cells into Osteogenic Differentiation. Stem Cells and Development, 2012, 21, 2420-2429.	1.1	68
40	Bone Balance within a Cortical BMU: Local Controls of Bone Resorption and Formation. PLoS ONE, 2012, 7, e40268.	1.1	6
41	Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. Journal of Clinical Investigation, 2012, 122, 4172-4189.	3.9	163
42	The 18 kDa Translocator Protein (Peripheral Benzodiazepine Receptor) Expression in the Bone of Normal, Osteoprotegerin or Low Calcium Diet Treated Mice. PLoS ONE, 2012, 7, e30623.	1.1	11
43	The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 2011, 48, 66-70.	1.4	25
44	Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone, 2011, 49, 733-742.	1.4	56
45	Burning daylight: balancing vitamin D requirements with sensible sun exposure. Medical Journal of Australia, 2011, 194, 345-348.	0.8	17
46	Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. PLoS ONE, 2011, 6, e27494.	1.1	37
47	Vitamin D deficiency promotes prostate cancer growth in bone. Prostate, 2011, 71, 1012-1021.	1.2	50
48	Theoretical analysis of the spatio-temporal structure of bone multicellular units. IOP Conference Series: Materials Science and Engineering, 2010, 10, 012132.	0.3	1
49	Genetic and hormonal control of bone volume, architecture, and remodeling in XXY mice. Journal of Bone and Mineral Research, 2010, 25, 2148-2154.	3.1	23
50	Theoretical investigation of the role of the RANKâ€“RANKLâ€“OPG system in bone remodeling. Journal of Theoretical Biology, 2010, 262, 306-316.	0.8	102
51	The incorporation of strontium and zinc into a calciumâ€“silicon ceramic for bone tissue engineering. Biomaterials, 2010, 31, 3175-3184.	5.7	261
52	Vitamin D Deficiency Promotes Human Breast Cancer Growth in a Murine Model of Bone Metastasis. Cancer Research, 2010, 70, 1835-1844.	0.4	131
53	Follicle-stimulating hormone increases bone mass in female mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22629-22634.	3.3	83
54	Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone, 2010, 47, 795-803.	1.4	65

#	Article	IF	Citations
55	Wnt7b plays a unique and essential role in osteoblast differentiation. Bone, 2010, 47, S370.	1.4	1
56	Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids, 2010, 75, 282-286.	0.8	13
57	Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development (Cambridge), 2009, 136, 427-436.	1.2	82
58	Bone growth is enhanced by novel bioceramic coatings on Ti alloy implants. Journal of Biomedical Materials Research - Part A, 2009, 90A, 419-428.	2.1	24
59	Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serumâ€“induced arthritis in vivo. Arthritis and Rheumatism, 2009, 60, 1998-2007.	6.7	49
60	Biphasic Glucocorticoid-Dependent Regulation of Wnt Expression and Its Inhibitors in Mature Osteoblastic Cells. Calcified Tissue International, 2009, 85, 538-545.	1.5	78
61	Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study. Acta Biomaterialia, 2009, 5, 3192-3204.	4.1	38
62	CXCL12/CXCR4 Axis in Tissue Targeting and Bone Destruction in Cancer and Multiple Myeloma. Journal of Bone and Mineral Research, 2009, 24, 1147-1149.	3.1	13
63	New insights into therapeutic drug interventions for catabolic bone diseases using an in-silico modeling approach. Bone, 2009, 44, S135-S136.	1.4	0
64	Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice. Bone, 2009, 45, 61-67.	1.4	64
65	The challenge of continuous exogenous glucocorticoid administration in mice. Steroids, 2009, 74, 245-249.	0.8	36
66	Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clinical and Experimental Metastasis, 2008, 25, 559-567.	1.7	45
67	Model structure and control of bone remodeling: A theoretical study. Bone, 2008, 43, 249-263.	1.4	237
68	Osteoblasts Directly Control Lineage Commitment of Mesenchymal Progenitor Cells through Wnt Signaling. Journal of Biological Chemistry, 2008, 283, 1936-1945.	1.6	134
69	Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clinical Practice Oncology, 2007, 4, 42-55.	4.3	111
70	Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone. Cancer Research, 2007, 67, 9542-9548.	0.4	55
71	RANK ligand. International Journal of Biochemistry and Cell Biology, 2007, 39, 1077-1081.	1.2	63
72	Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 2007, 40, 471-478.	1.4	82

#	Article	IF	Citations
73	Sex Steroids, Not FSH, Influence Bone Mass. Cell, 2006, 127, 1079.	13.5	42
74	The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases. , 2006, , 51-62.		0
75	The Receptor Activator of Nuclear Factor-ÎºB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism. Calcified Tissue International, 2006, 78, 35-44.	1.5	39
76	The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism, 2006, 54, 1772-1777.	6.7	158
77	Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 2006, 3, 41-49.	4.3	128
78	Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 2006, 3, E1-E1.	4.3	2
79	Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clinical Laboratory, 2006, 52, 1-10.	0.2	47
80	A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. Journal of Bone and Mineral Research, 2005, 20, 2274-2282.	3.1	45
81	The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology, 2005, 146, 3235-3243.	1.4	95
82	Combined treatment with PTH (1â€“34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone, 2005, 37, 87-95.	1.4	44
83	Fibroblast Growth Factor 23: A Phosphatonin Regulating Phosphate Homeostasis?. Endocrinology, 2004, 145, 3084-3086.	1.4	20
84	Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor ÎºB ligand and MAPK. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 1-7.	1.9	42
85	A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. Journal of Bone and Mineral Research, 2004, 19, 1059-1066.	3.1	657
86	The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis, 2004, 21, 381-387.	1.7	52
87	Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis and Rheumatism, 2004, 50, 277-290.	6.7	297
88	Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Experimental Cell Research, 2004, 293, 292-301.	1.2	50
89	Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats. Journal of Bone and Mineral Research, 2003, 18, 852-858.	3.1	94
90	Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporosis International, 2003, 14, 728-733.	1.3	75

#	Article	IF	Citations
91	A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 2003, 97, 887-892.	2.0	347
92	Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis and Rheumatism, 2003, 48, 2042-2051.	6.7	132
93	Markers of Bone Remodeling in Metastatic Bone Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5059-5075.	1.8	106
94	Regulation of osteoclast protease expression by RANKL. Biochemical and Biophysical Research Communications, 2003, 310, 774-778.	1.0	47
95	Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin. Immunity, 2003, 19, 849-861.	6.6	149
96	A Toxicity Profile of Osteoprotegerin in the Cynomolgus Monkey. International Journal of Toxicology, 2003, 22, 403-412.	0.6	33
97	Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11201-11206.	3.3	393
98	A Toxicity Profile of Osteoprotegerin in the Cynomolgus Monkey. International Journal of Toxicology, 2003, 22, 403-412.	0.6	1
99	Rationale for the role of osteoclastâ€like cells in arterial calcification. FASEB Journal, 2002, 16, 577-582.	0.2	94
100	Effect of EstrogenversusTestosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1550-1554.	1.8	167
101	Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. American Journal of Pathology, 2002, 161, 1419-1427.	1.9	352
102	Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochemical and Biophysical Research Communications, 2002, 293, 38-44.	1.0	55
103	Tumor necrosis factor Î±-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis and Rheumatism, 2002, 46, 785-792.	6.7	258
104	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. Journal of Cellular Biochemistry, 2002, 86, 642-650.	1.2	35
105	Correlates of Osteoprotegerin Levels in Women and Men. Osteoporosis International, 2002, 13, 394-399.	1.3	177
106	Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 2002, 8, 2306-10.	3.2	97
107	Effects of Immunosuppressants on Receptor Activator of NF-Î²B Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells. Biochemical and Biophysical Research Communications, 2001, 280, 334-339.	1.0	196
108	Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 2001, 98, 3534-3540.	0.6	344

#	Article	IF	Citations
109	Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. Journal of Orthopaedic Research, 2001, 19, 518-523.	1.2	15
110	The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women. Journal of Bone and Mineral Research, 2001, 16, 348-360.	3.1	418
111	The effects of osteoprotegerin on the mechanical properties of rat bone. Journal of Materials Science: Materials in Medicine, 2001, 12, 583-588.	1.7	30
112	Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis. Molecular Therapy, 2001, 3, 197-205.	3.7	93
113	OPG and PTH-(1â€“34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. Endocrinology, 2001, 142, 4295-4304.	1.4	121
114	OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. Endocrinology, 2001, 142, 4295-4304.	1.4	34
115	Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Research, 2001, 61, 4432-6.	0.4	234
116	Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clinical Cancer Research, 2001, 7, 2977-83.	3.2	87
117	Osteoprotegerin and Osteoprotegerin Ligand Mediate the Local Regulation of Bone Resorption. , 2000, 10, 18-26.		22
118	Characterization of osteoclast precursors in human blood. British Journal of Haematology, 2000, 111, 501-512.	1.2	15
119	The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption. Journal of Bone and Mineral Research, 2000, 15, 2-12.	3.1	1,031
120	RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1566-1571.	3.3	1,004
121	Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis. Journal of Experimental Medicine, 2000, 192, 463-474.	4.2	494
122	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated**This work was supported by Grant AG-04875 from the National Institute on Aging.. Endocrinology, 2000, 141, 4768-4776.	1.4	255
123	Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone, 2000, 26, 443-449.	1.4	62
124	Characterization of osteoclast precursors in human blood. British Journal of Haematology, 2000, 111, 501-512.	1.2	112
125	Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2000, 111, 608-617.	1.2	35
126	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated. Endocrinology, 2000, 141, 4768-4776.	1.4	68

#	Article	IF	Citations
127	Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Research, 2000, 60, 783-7.	0.4	109
128	Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells*. Endocrinology, 1999, 140, 4367-4370.	1.4	589
129	Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3540-3545.	3.3	1,495
130	The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts. Journal of Cell Biology, 1999, 145, 527-538.	2.3	634
131	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. Endocrinology, 1999, 140, 4382-4389.	1.4	690
132	OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397, 315-323.	13.7	3,093
133	Systemic Administration of Acidic Fibroblast Growth Factor (FGF-1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized Rats. Journal of Bone and Mineral Research, 1999, 14, 953-959.	3.1	110
134	A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL-1Î², TNF-Î±, PTH, PTHrP, and 1,25(OH)2D3. Journal of Bone and Mineral Research, 1999, 14, 1478-1485.	3.1	171
135	Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. Journal of Cellular Biochemistry, 1999, 72, 251-261.	1.2	116
136	Interleukin-1Î² and tumor necrosis factor-Î±, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 1999, 25, 255-259.	1.4	575
137	TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes and Development, 1999, 13, 1015-1024.	2.7	1,146
138	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. Endocrinology, 1999, 140, 4382-4389.	1.4	204
139	Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells. Endocrinology, 1999, 140, 4367-4370.	1.4	164
140	Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide. Clinical and Experimental Metastasis, 1998, 16, 645-654.	1.7	9
141	Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation. Cell, 1998, 93, 165-176.	13.5	4,946
142	Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines. Biochemical and Biophysical Research Communications, 1998, 250, 776-781.	1.0	283
143	osteoprotegerin-deficient mice develop early onset osteoporosis and arterialÂcalcification. Genes and Development, 1998, 12, 1260-1268.	2.7	2,176
144	Bone Resorption Caused by Three Periodontal Pathogens In Vivo in Mice Is Mediated in Part by Prostaglandin. Infection and Immunity, 1998, 66, 4158-4162.	1.0	67

#	Article	IF	Citations
145	Bone Resorption Caused by Three Periodontal Pathogens In Vivo in Mice Is Mediated in Part by Prostaglandin. Infection and Immunity, 1998, 66, 4158-4162.	1.0	11
146	Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell, 1997, 89, 309-319.	13.5	4,620
147	Mitogenic Lectin Concanavalin A Induces Calvarial Bone Formation In Vivo via Indomethacin-Sensitive Pathway. Calcified Tissue International, 1997, 60, 204-209.	1.5	3
148	Effects of Human Tumor Cell Lines on Local New Bone Formation In Vivo. Calcified Tissue International, 1997, 60, 210-215.	1.5	10
149	Bone Morphogenetic Protein 2 (BMP-2) Enhances BMP-3, BMP-4, and Bone Cell Differentiation Marker Gene Expression During the Induction of Mineralized Bone Matrix Formation in Culturesof Fetal Rat Calvarial Osteoblasts. Calcified Tissue International, 1997, 60, 283-290.	1.5	218
150	Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.. Journal of Clinical Investigation, 1997, 99, 2509-2517.	3.9	217
151	Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Research, 1997, 57, 3194-9.	0.4	46
152	Increased bone formation in osteocalcin-deficient mice. Nature, 1996, 382, 448-452.	13.7	1,522
153	Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Cancer Research, 1996, 56, 633-6.	0.4	25
154	E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Research, 1996, 56, 4063-70.	0.4	128
155	The effects of cytokines and growth factors on osteoblastic cells. Bone, 1995, 17, S71-S75.	1.4	118
156	Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. Cancer Research, 1995, 55, 1989-93.	0.4	12
157	The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporosis International, 1993, 3, 71-75.	1.3	29
158	Osteocyte death and hip fracture. Calcified Tissue International, 1993, 53, S113-S117.	1.5	83
159	Aluminium-related Bone Disease Presenting with Calcaneal Stress Fractures. Rheumatology, 1993, 32, 260-261.	0.9	1
160	Measurement of osteoclasts and bone resorption by automated image analysis. Journal of Bone and Mineral Research, 1993, 8, 139-145.	3.1	4
161	Bone death in transient regional osteoporosis. Bone, 1992, 13, 161-165.	1.4	47
162	Prurigo riodularis and aluminium overload in maintenance haemodialysis. Lancet, The, 1992, 340, 48.	6.3	58

#	Article	IF	Citations
163	Bone loss after liver transplantation. Hepatology, 1991, 14, 613-619.	3.6	182
164	Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide. Calcified Tissue International, 1991, 49, 164-167.	1.5	5
165	Bone loss after liver transplantation. Hepatology, 1991, 14, 613-619.	3.6	31
166	Letters to the Editor. Journal of Bone and Mineral Research, 1990, 5, 419-420.	3.1	1
167	Bone death in hip fracture in the elderly. Calcified Tissue International, 1990, 47, 270-275.	1.5	54
168	Measurement of bone in the os calcis: A clinical evaluation. Journal of Bone and Mineral Research, 1989, 4, 507-514.	3.1	13
169	The effectiveness of a soluble calcium preparation as a gut phosphate binder. Metabolism: Clinical and Experimental, 1988, 37, 815-819.	1.5	6
170	Recovery from Steroid-Induced Osteoporosis. Annals of Internal Medicine, 1987, 107, 319.	2.0	130
171	Limitations of bone biopsy. Bone, 1985, 6, 401-401.	1.4	6
172	Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure. Calcified Tissue International, 1984, 36, 133-138.	1.5	52
173	Adult osteosclerosis. Metabolic Bone Disease & Related Research, 1983, 5, 111-117.	0.5	6
174	Bone metabolism in idiopathic juvenile osteoporosis: A case report. Calcified Tissue International, 1983, 35, 5-8.	1.5	25
175	Effect of aluminum on normal and uremic rats: Tissue distribution, vitamin D metabolites, and quantitative bone histology. Calcified Tissue International, 1983, 35, 344-351.	1.5	101
176	Growth retardation and renal osteodystrophy in children with chronic renal failure. Journal of Pediatrics, 1983, 103, 735-740.	0.9	32
177	PATHOLOGIC FRACTURE DUE TO SEVERE OSTEOMALACIA FOLLOWING LOWâ€ÐOSE DIPHOSPHONATE TREATMENT OF PAGET'S DISEASE OF BONE. Australian and New Zealand Journal of Medicine, 1983, 13, 277-279.	0.5	21
178	Quantitative Bone Histology in the Hypercalcemia of Malignant Disease*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 1066-1072.	1.8	29
179	The Effect of Long-Term Low-Dose Diphosphonate Treatment on Rat Bone. Clinical Orthopaedics and Related Research, 1982, &NA;, 290???299.	0.7	24
180	Quantitative bone histology in children with chronic renal failure. Kidney International, 1982, 21, 833-839.	2.6	23

#	Article	IF	Citations
181	Lack of Metabolic Bone Disease in Patients with Fracture of the Femoral Neck*. Australian and New Zealand Journal of Medicine, 1981, 11, 158-161.	0.5	30
182	Quantitative bone histology: A new method. Pathology, 1980, 12, 255-264.	0.3	33
183	The Pathogenesis of Renal Osteodystrophy: Role of Vitamin D, Aluminium, Parathyroid Hormone, Calcium and Phosphorus. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	2